CICC International: Raises target price of Sino Biopharmaceutical (02096) to HK$14.3, maintains "buy" rating.

According to the Wisdom Finance app, CICC released a research report stating that it maintains a "buy" rating on Sino Biopharmaceutical (02096), with a target price of 14.3 Hong Kong dollars, and maintains a key recommendation for the industry. It has raised its net profit forecast for the company for 2025-2027 by 6-11%. It is optimistic about the potential for more overseas transactions to be completed in the short term and suggests focusing on high-profile targets such as CDH6 and CDH17.